Serina Therapeutics, Inc. (SER)

Price$1.88

Value ScoreD

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-63.79%

Price vs S&P 500 (4W)7.44%

VGM Score43.27

Market Capitalization$28.20M

All Metrics

Book Value / Share (Quarterly)$1.18

Revenue Growth (3Y)63.03%

Cash Flow / Share (Quarterly)$-1.23

Price vs S&P 500 (YTD)-9.88%

Gross Margin (TTM)65.07%

Net Profit Margin (TTM)-3498.61%

EPS (TTM)$-1.89

10-Day Avg Trading Volume0.09M

EPS Excl Extra (TTM)$-1.89

Revenue Growth (5Y)-18.43%

EPS (Annual)$-1.88

ROI (Annual)-1738.07%

Gross Margin (Annual)71.83%

Net Profit Margin (5Y Avg)-17228.27%

Cash / Share (Quarterly)$1.65

Revenue Growth QoQ (YoY)154.90%

ROA (Last FY)-275.96%

Revenue Growth TTM (YoY)3.17%

EBITD / Share (TTM)$-2.28

ROE (5Y Avg)-549.42%

Operating Margin (TTM)-7553.47%

Cash Flow / Share (Annual)$-1.67

P/B Ratio1.60x

P/B Ratio (Quarterly)1.36x

Net Income / Employee (Annual)$-1,198,900

EV / Revenue (TTM)46.38x

Net Interest Coverage (TTM)-89.13x

ROA (TTM)-219.00%

EPS Incl Extra (Annual)$-1.88

Current Ratio (Annual)1.71x

Quick Ratio (Quarterly)3.92x

3-Month Avg Trading Volume3.16M

52-Week Price Return-68.40%

Revenue / Employee (TTM)$8,100

P/S Ratio (Annual)216.89x

Asset Turnover (Annual)0.02x

52-Week High$7.92

Operating Margin (5Y Avg)-16851.61%

EPS Excl Extra (Annual)$-1.88

CapEx CAGR (5Y)24.16%

26-Week Price Return-55.87%

Quick Ratio (Annual)0.94x

13-Week Price Return19.75%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.18x

Enterprise Value$6.68M

Revenue / Share Growth (5Y)5.92%

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$8,100

Pretax Margin (Annual)-14766.92%

Cash / Share (Annual)$0.28

3-Month Return Std Dev222.52%

Gross Margin (5Y Avg)82.27%

Net Income / Employee (TTM)$-1,198,900

ROE (Last FY)-1738.07%

Net Interest Coverage (Annual)-66.49x

EPS Basic Excl Extra (Annual)$-1.88

Receivables Turnover (TTM)3.76x

Total Debt / Equity (Quarterly)0.17x

EPS Incl Extra (TTM)$-1.89

Receivables Turnover (Annual)4.98x

ROI (TTM)-583.22%

P/S Ratio (TTM)195.80x

Pretax Margin (5Y Avg)-17280.99%

Revenue / Share (Annual)$0.01

Price vs S&P 500 (52W)-92.77%

Year-to-Date Return-1.73%

5-Day Price Return3.87%

EPS Normalized (Annual)$-1.88

ROA (5Y Avg)-232.75%

Net Profit Margin (Annual)-14755.38%

Month-to-Date Return2.17%

EBITD / Share (Annual)$-2.28

Operating Margin (Annual)-17921.54%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-480.73%

LT Debt / Equity (Quarterly)0.17x

EPS Basic Excl Extra (TTM)$-1.89

P/B Ratio (Annual)69.50x

Pretax Margin (TTM)-3527.08%

Book Value / Share (Annual)$0.07

Price vs S&P 500 (13W)11.49%

Beta7.53x

Revenue / Share (TTM)$0.01

ROE (TTM)-903.25%

52-Week Low$1.22

vGradeD

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.58est. -0.44

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
SERSerina Therapeutics, Inc.	D	C	C	$1.88
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates for neurological diseases and pain management. The company's proprietary POZ Platform provides controlled drug loading and precise release mechanisms, offering advantages over traditional polymer-based delivery systems. Serina is focused on addressing limitations of existing technologies to enable treatment of challenging small-molecule drugs.